|
🐜
|
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
19 auth.
J. Apperley,
M. Gardembas,
J. Melo,
R. Russell‐Jones,
B. Bain,
E. Baxter,
A. Chase,
J. Chessells,
Marie Colombat,
C. Dearden,
...
S. Dimitrijević,
F. Mahon,
D. Marin,
Z. Nikolova,
E. Olavarría,
S. Silberman,
B. Schultheis,
N. Cross,
J. Goldman
|
9 |
2002 |
9
🐜
|
|
🐜
|
Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas.
11 auth.
E. Vonderheid,
M. Bernengo,
G. Burg,
M. Duvic,
P. Heald,
L. Laroche,
...
E. Olsen,
M. Pittelkow,
R. Russell‐Jones,
M. Takigawa,
R. Willemze
|
8 |
2002 |
8
🐜
|
|
🐜
|
WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects
28 auth.
G. Burg,
W. Kempf,
A. Cozzio,
J. Feit,
R. Willemze,
Elaine S Jaffe,
R. Dummer,
E. Berti,
L. Cerroni,
S. Chimenti,
J. Díaz-Pérez,
F. Grange,
N. Harris,
D. Kazakov,
H. Kerl,
...
M. Kurrer,
R. Knobler,
C. Meijer,
N. Pimpinelli,
E. Ralfkiaer,
R. Russell‐Jones,
C. Sander,
M. Santucci,
W. Sterry,
S. Swerdlow,
M. Vermeer,
J. Wechsler,
S. Whittaker
|
8 |
2005 |
8
🐜
|
|
🐜
|
Cytotoxic/natural killer cell cutaneous lymphomas
24 auth.
M. Santucci,
N. Pimpinelli,
D. Massi,
M. Kadin,
C. Meijer,
H. Müller-hermelink,
M. Paulli,
J. Wechsler,
R. Willemze,
H. Audring,
...
M. Bernengo,
L. Cerroni,
S. Chimenti,
A. Chott,
J. Díaz-Pérez,
E. Dippel,
L. Duncan,
A. Feller,
M. Geerts,
C. Hallermann,
W. Kempf,
R. Russell‐Jones,
C. Sander,
E. Berti
|
7 |
2003 |
7
🐜
|
|
🐬
|
Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas.
X. Mao,
G. Orchard,
D. Lillington,
R. Russell‐Jones,
B. Young,
S. Whittaker
|
7 |
2003 |
7
🐬
|
|
🐜
|
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
24 auth.
M. Dávid,
N. Cross,
S. Burgstaller,
A. Chase,
Claire Curtis,
R. Dang,
M. Gardembas,
J. Goldman,
F. Grand,
G. Hughes,
...
F. Huguet,
L. Lavender,
G. McArthur,
F. Mahon,
G. Massimini,
J. Melo,
P. Rousselot,
R. Russell‐Jones,
J. Seymour,
Graeme N. Smith,
A. Stark,
K. Waghorn,
Z. Nikolova,
J. Apperley
|
7 |
2007 |
7
🐜
|
|
🐜
|
Mucocutaneous sarcoidosis treated with mycophenolate mofetil
8 auth.
S.M. Cooper,
G.D.H. Turner,
K. Hollowood,
K. Gatter,
C. Hatton,
D. Gray,
...
R. Russell‐Jones,
F. Wojnarowska
|
7 |
2002 |
7
🐜
|
|
🐜
|
A Shift in the Phenotype of Melan-A-Specific CTL Identifies Melanoma Patients with an Active Tumor-Specific Immune Response1
13 auth.
P. Dunbar,
Caroline L. Smith,
D. Chao,
M. Salio,
D. Shepherd,
F. Mirza,
M. Lipp,
A. Lanzavecchia,
F. Sallusto,
A. Evans,
...
R. Russell‐Jones,
A. Harris,
V. Cerundolo
|
7 |
2000 |
7
🐜
|
|
🐬
|
Detection of a peripheral blood T cell clone is an independent prognostic marker in mycosis fungoides.
E. Fraser-Andrews,
A. Woolford,
R. Russell‐Jones,
Paul T. Seed,
S. Whittaker
|
7 |
2000 |
7
🐬
|
|
🐢
|
Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma.
7 auth.
J. Scarisbrick,
S. Whittaker,
A. Evans,
E. Fraser-Andrews,
F. Child,
A. Dean,
...
R. Russell‐Jones
|
7 |
2001 |
7
🐢
|
|
🐢
|
Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD)
8 auth.
Fiona Child,
R. Ratnavel,
P. Watkins,
D. Samson,
J. Apperley,
J. Ball,
...
P. Taylor,
R. Russell‐Jones
|
7 |
1999 |
7
🐢
|
